^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QBS72S

    i
    Other names: QBS72S, QBS10072S, QBS-72S, QBS'72S
    Associations

    News

    Trials
    Company:
    Quadriga Biosci
    Drug class:
    Alkylating agent
    Related drugs:
    Associations

    News

    Trials
    1m
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=460, Recruiting, Patrick Wen, MD | Trial completion date: Dec 2025 --> Apr 2027 | Trial primary completion date: Mar 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • QBS72S
    5ms
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=460, Recruiting, Patrick Wen, MD | N=250 --> 460
    Enrollment change
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    temozolomide • Nerlynx (neratinib) • QBS72S
    9ms
    Study Assessing QBS72S For Treating Brain Metastases (clinicaltrials.gov)
    P2, N=40, Recruiting, Melanie Hayden Gephart | Phase classification: P2a --> P2
    Phase classification
    |
    QBS72S
    11ms
    Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas. (PubMed, Leuk Res Rep)
    The findings demonstrated decreased survival of T-cell lymphoma lines with both compounds. Overall, the results demonstrate that LAT1 is a valuable biomarker for aggressive T-cell lymphoma counterparts and QBS10072S and QBS10096S are successful therapeutic options for these aggressive diseases.
    Journal
    |
    SLC7A5 (Solute Carrier Family 7 Member 5)
    |
    QBS72S
    over1year
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=250, Recruiting, Patrick Wen, MD | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • QBS72S
    over1year
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=250, Recruiting, Patrick Wen, MD | Active, not recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • QBS72S
    2years
    Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer (clinicaltrials.gov)
    P2a, N=35, Recruiting, Melanie Hayden Gephart | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR expression
    |
    QBS72S
    over2years
    Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer (clinicaltrials.gov)
    P2a, N=35, Not yet recruiting, Melanie Hayden Gephart | Initiation date: Apr 2022 --> Jul 2022
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR expression
    |
    QBS72S
    over2years
    Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer (clinicaltrials.gov)
    P2a, N=35, Not yet recruiting, Melanie Hayden Gephart
    New P2a trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR expression
    |
    QBS72S
    almost3years
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (clinicaltrials.gov)
    P2, N=250, Active, not recruiting, Patrick Y. Wen, MD | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • QBS72S
    3years
    A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma. (PubMed, Cureus)
    Introduction The standard treatment for glioblastoma (GBM) patients is surgical tumor resection, followed by radiation and chemotherapy with temozolomide (TMZ). In orthotopic GBM xenografts, QBS10072S treatment significantly delayed tumorigenesis and prolonged animal survival compared to the vehicle without adverse effects. Conclusion QBS10072S is a novel BBB-permeable chemotherapeutic agent with the potential to treat TMZ-resistant and recurrent GBM as monotherapy or in combination with radiation treatment.
    Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    temozolomide • QBS72S